Thursday, April 04, 2024

PALEONTOLOGY

Early dinosaurs grew up fast, but they weren’t the only ones



High growth rates apparently a common feature among early Mesozoic animals


PLOS

Osteohistological insight into the growth dynamics of early dinosaurs and their contemporaries 

IMAGE: 

HERRERASAURUS ISCHIGUALASTENSIS IS AN EARLY SAURISCHIAN DINOSAUR. IT SHARED A BIPEDAL, RUNNING ANATOMY COMMON TO LARGE CARNIVOROUS DINOSAURS THAT WOULD EVOLVE IN THE FUTURE, BUT THIS DINOSAUR LIVED AT A TIME WHEN DINOSAURS WERE SMALL-BODIED AND RARE. 

view more 

CREDIT: KRISTINA CURRY ROGERS (ILLUSTRATION BY JORDAN HARRIS, CC-BY 4.0 (HTTPS://CREATIVECOMMONS.ORG/LICENSES/BY/4.0/)




The earliest dinosaurs had rapid growth rates, but so did many of the other animals living alongside them, according to a study published April 3, 2024 in the open-access journal PLOS ONE by Kristina Curry Rogers of Macalester College, Minnesota and colleagues.

Dinosaurs grew up fast, a feature that likely set them apart from many other animals in their Mesozoic (252 to 66 million years ago) ecosystems. Some researchers have proposed that these elevated growth rates were key to the global success of dinosaurs, but little is known about the growth strategies of the earliest dinosaurs. In this study, Rogers and colleagues performed histological analysis, examining patterns of bone tissue growth in the fossilized leg bones of an array of animals in one of the earliest known Mesozoic ecosystems.

The studied fossils come from the Ischigualasto Formation of Argentina and date between 231-229 million years old. Sampled fossils include several of the earliest known dinosaurs as well as several non-dinosaur reptiles and one early relative of mammals.

The analysis found that most of the examined species had elevated growth rates, more similar to some modern-day mammals and birds than to living reptiles. The early dinosaurs all exhibited particularly fast growth, but they weren’t alone in this, as similar growth rates were seen in several of the non-dinosaur reptiles as well.

These results show that the earliest dinosaurs were already fast growers, supporting the idea that this feature was important to their later success. But apparently dinosaurs were only one of multiple lineages evolving with elevated growth rates during the Triassic (252-201 million years ago), suggesting that this feature is only part of the story of dinosaurs’ eventual global prosperity. The authors note that future studies could expand on these preliminary results by sampling a wider variety of ancient animals from additional early Mesozoic fossil sites.

The authors add: “Our sample comes from a time in which dinosaurs were the new kids on the block, restricted to relatively small, basic body plans, and evolving within a world rich with a diverse array of more specialized, non-dinosaur reptiles. We tackled the question of how all of these animals grew, and found that the earliest dinosaurs grew quickly, and that these rapid growth rates probably played a significant role in dinosaurs’ subsequent ascent within Mesozoic ecosystems; but dinosaurs weren’t unique – many of their non-dino sidekicks shared rapid growth 230 million years ago.”

#####

In your coverage please use this URL to provide access to the freely available article in PLOS ONEhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0298242

Citation: Curry Rogers K, Martínez RN, Colombi C, Rogers RR, Alcober O (2024) Osteohistological insight into the growth dynamics of early dinosaurs and their contemporaries. PLoS ONE 19(4): e0298242. https://doi.org/10.1371/journal.pone.0298242

Author Countries: USA, Argentina

Funding: This work was supported the National Science Foundation CAREER Grant – EAR-0955716 to KCR and by the Wallace Faculty Travel Grant from Macalester College to KCR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

 

JAMA paper: In people with opioid use disorder, telemedicine treatment for HCV was more than twice as successful as off-site referral


While the study was complex in design, both participants and treatment center staff became enthusiastic supporters because of the value of an HCV cure


Peer-Reviewed Publication

UNIVERSITY AT BUFFALO

Andrew Talal, MD with telemedicine setup 

IMAGE: 

TALAL SAYS THE RESULTS OF THE STUDY INDICATE THAT TELEMEDICINE CAN BE AN IMPORTANT WAY TO IMPROVE ACCESS TO HEALTH CARE FOR UNDERSERVED POPULATIONS.

view more 

CREDIT: SANDRA KICMAN




BUFFALO, N.Y. – People with opioid use disorder who have hepatitis C virus (HCV) were twice as likely to be successfully treated and cured from HCV if they received facilitated telemedicine treatment at their opioid treatment program (OTPs) than if they were referred off-site to another provider. Those are the findings published today by a University at Buffalo team of researchers in the Journal of the American Medical Association (JAMA).

The study is one of only a few randomized controlled trials that have been conducted to determine the effectiveness of using telemedicine to improve health care access for vulnerable populations.

These groundbreaking results published in JAMA highlight the power of novel approaches in tackling chronic conditions in underserved populations,” says Allison Brashear, MD, vice president for health sciences and dean of the Jacobs School of Medicine and Biomedical Sciences at UB. “The findings pave the way for significant improvements in the lives of participants and offer hope for similar successes in addressing other diseases.”

Individuals with opioid use disorder are a particularly challenging underserved population to treat in conventional health care settings, and they are at highest risk for hepatitis C virus infection through needle sharing.

Led by Andrew H. Talal, MD, professor of medicine in the Jacobs School, this study explored the effectiveness of integrating telemedicine into OTPs for HCV management, thereby removing the need for off-site referrals.

It was funded by an $8.2 million award from the Patient-Centered Outcomes Research Institute (PCORI) to compare OTP-integrated facilitated telemedicine to off-site referral to an HCV specialist, the usual care approach in treating HCV in these individuals.

In addition, the Troup Fund of the Kaleida Health Foundation provided more than $3 million to the research.

Ninety percent were cured

The study was conducted from 2017 to 2022 at 12 OTPs in New York State that dispense methadone. Researchers enrolled 602 participants with opioid use disorder who had been diagnosed with HCV. Participants received treatment with direct acting antiviral medications for HCV and were followed for two years after being cured to evaluate for reinfection.

The researchers found that 90.3% of those in the telemedicine arm at an OTP were cured of HCV infection compared to 39.4% of participants referred to an off-site specialist. Two-thirds of those in the referral arm never initiated HCV treatment at all.

During two years of follow-up, there were minimal HCV reinfections.

“Telemedicine leads to high patient retention in care and cure within this population,” says Talal.

The researchers also found that being cured of HCV resulted in subsequent health and well-being improvements for participants, including significant reductions in substance use.

After initiating treatment for opioid use disorder, combined with an HCV cure, many individuals were able to successfully seek employment, improve their education status and reduce their involvement with the criminal justice system.

A key advantage was the use of facilitated telemedicine, where telemedicine is integrated into settings where patients are already receiving treatment — in this case, methadone. Since the participants already had strong and established relationships with staff, it was relatively straightforward to provide HCV treatment at the same time.

It was a relatively complex study, where each arm of the study was implemented at each site but at different times. Talal held regular brown bag lunches with OTP staff and patients to directly answer questions and concerns, and to educate them about the infection.

Tangible win

The potential advantages were easy to see. “We had the opportunity to engage in a treatment modality to address a chronic condition that’s secondary to opioid use,” says Ken Bossert, who was an administrator at the Drug Abuse Research & Treatment (DART) site in Buffalo. “We could nearly guarantee clients would be cured, and we stressed that once cured, they shouldn’t re-expose themselves to risk. So now the patient could say, ‘OK, I participate in this study, I’m starting to feel better, and this chronic condition goes away.’ It’s a tangible win.”

It was a win-win for researchers, OTP staff and participants.

“Our findings show that this kind of research can be done in unconventional settings and that leveraging the trust that patients have in these treatment programs can be very helpful,” says Talal.

The findings also demonstrate a key benefit of telemedicine: It improves health care access for people with opioid use disorder who typically encounter shunning and stigma in conventional health care settings.

“Our study demonstrates how telemedicine successfully integrates medical and behavioral treatment,” he says.

The results demonstrate that telemedicine should be further investigated as an approach to increase health care access for underserved populations experiencing other health conditions.

In addition to his role in the Jacobs School, Talal is a physician with UBMD Internal Medicine. He conducts numerous clinical trials on new treatments for liver disease, including HCV. He also is a member of the task force that advises the state on its New York State HCV Elimination Plan, as well as chair of the New York State HCV Telemedicine workgroup.

Along with Talal, UB co-authors are Marianthi Markatou, PhD, SUNY Distinguished Professor in the Department of Medicine in the Jacobs School and the Department of Biostatistics in the School of Public Health and Health Professions; Anran Liu, doctoral student in the Department of Biostatistics; Lawrence Brown, MD,  formerly of START Treatment & Recovery Centers; Ponni Perumalswami, MD, and Amreen Dinani, MD, both formerly of Ichan School of Medicine at Mt. Sinai; and Jonathan Tobin, PhD, of Clinical Directors Network and Rockefeller University.

Disclaimer: This work was supported by a Patient-Centered Outcomes Research Institute (PCORI) Award (IHS-1507-31640) and is partially supported by the Troup Fund of the Kaleida Health Foundation. The statements in this work are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors or Methodology Committee.

 

Does methylene blue or mitoquinone improve skeletal aging?



Peer-Reviewed Publication

IMPACT JOURNALS LLC

Figure 5 

IMAGE: 

FIGURE 5. ADMINISTRATION OF MB DURING AGING DOES NOT ALTER TRABECULAR BONE MORPHOLOGY OF THE AXIAL SKELETON.

view more 

CREDIT: 2024 POUDEL ET AL.




“[...] long-term administration of MB or MitoQ did not have an effect on skeletal morphology during the aging process [...]”

BUFFALO, NY- April 3, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 6, entitled, “Targeting mitochondrial dysfunction using methylene blue or mitoquinone to improve skeletal aging.”

Methylene blue (MB) is a well-established antioxidant that has been shown to improve mitochondrial function in both in vitro and in vivo settings. Mitoquinone (MitoQ) is a selective antioxidant that specifically targets mitochondria and effectively reduces the accumulation of reactive oxygen species. In this new study, researchers Sher Bahadur Poudel, Dorra Frikha-Benayed, Ryan R. Ruff, Gozde Yildirim, Manisha Dixit, Ron Korstanje, Laura Robinson, Richard A. Miller, David E. Harrison, John R. Strong, Mitchell B. Schaffler, and Shoshana Yakar from New York University College of DentistryCity College of New YorkThe Jackson LaboratoryUniversity of MichiganSouth Texas Veterans Health Care System, and The University of Texas Health Science Center investigated the effect of long-term administration of MB or MitoQ on skeletal morphology during the aging process.

“[...] we administered MB to aged (18 months old) female C57BL/J6 mice, as well as to adult male and female mice with a genetically diverse background (UM-HET3). Additionally, we used MitoQ as an alternative approach to target mitochondrial oxidative stress during aging in adult female and male UM-HET3 mice.”

Although the researchers observed some beneficial effects of MB and MitoQ in vitro, the administration of these compounds in vivo did not alter the progression of age-induced bone loss. Specifically, treating 18-month-old female mice with MB for 6 or 12 months did not have an effect on age-related bone loss. Similarly, long-term treatment with MB from 7 to 22 months or with MitoQ from 4 to 22 months of age did not affect the morphology of cortical bone at the mid-diaphysis of the femur, trabecular bone at the distal-metaphysis of the femur, or trabecular bone at the lumbar vertebra-5 in UM-HET3 mice.

“Based on our findings, it appears that long-term treatment with MB or MitoQ alone, as a means to reduce skeletal oxidative stress, is insufficient to inhibit age-associated bone loss. This supports the notion that interventions solely with antioxidants may not provide adequate protection against skeletal aging.”

 

Read the full paper: DOI: https://doi.org/10.18632/aging.205147 

Corresponding Author: Shoshana Yakar

Corresponding Email: sy1007@nyu.edu 

Keywords: methylene blue, mitoquinone, bone, micro-CT, antioxidants

Click here to sign up for free Altmetric alerts about this article.

 

About Aging:

Aging publishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer’s diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.

Aging is indexed by PubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed CentralWeb of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

Please visit our website at www.Aging-US.com​​ and connect with us:

 

Click here to subscribe to Aging publication updates.

 

Study: Vanishing photos make dating app matches multiply


Snapchat-like photo sharing can lead to better outcomes for those using dating apps



TULANE UNIVERSITY




Because of catfishing and other dating scams, privacy is essential on online dating sites, even more so than other places online. However, these privacy concerns can make people reticent to share the very personal information that could help them make a connection with someone. 

A new Tulane University study finds that sharing ephemeral photos, which vanish after being seen, can increase the number of matches on a dating app. The study was published in Information Systems Research.

Popularized by the app Snapchat, ephemeral sharing is a type of digital design wherein the person receiving information, like a photo, can only view it for a limited amount of time after which it becomes invisible and non-retrievable. Because the information disappears, people tend to be more willing to share personal information because of the higher level of privacy it affords, said lead study author Yumei He, assistant professor of management science at Tulane’s A. B. Freeman School of Business.

“Usually people on dating platforms are strangers, and they have privacy concerns,” said He. Because of the proliferation of things like dating scams, she said “the privacy issue is more substantial on dating platforms. What if my information now gets abused, or I get identified by somebody else, my friends or acquaintances?”

The study, which was conducted using a popular dating app in China, found that enabling people to share in the moment helped them overcome the “communication cold-start problem,” which is a phenomenon where people are loath to share personal information with new people on dating apps. The issue makes it more difficult to have conversations that could lead to a deeper connection. 

Because people were more likely to share photos when they were ephemeral, users ended up with more matches and had more conversations once they matched. 

Before starting the study, He’s team wanted to check whether the ephemeral sharing would increase the amount of unwanted photos, like images with sexual or other inappropriate content. Her team found no significant difference in the ratio of toxic photos between ephemeral and normal sharing. “This is critical, because that means that feature is creating some benefit without compromising the courtesy for sending a photo,” said He. 

This is likely due to an important difference between sharing ephemeral photos on social media, where users likely already know the people they are sharing information with, and on dating sites, where users are strangers. On dating apps, He said, “people still want to preserve a good self-image or present themselves in order to get a quality match.”

This means that, even with ephemeral sharing, people don’t tend to be as emotional or disinhibited on dating sites as they are amongst people they already know on social media. 

“It is because people share more photos that are ephemeral, instead of a content change, that leads to more matches or the receiver’s conversation,” said He. 

This research was done in conjunction with Xingchen Xu from the University of Washington, Ni Huang and Kevin Hong from the University of Miami, and De Liu from the University of Minnesota.  

 

Binghamton University receives $1 million to support job training in electronics manufacturing


New cleanroom equipment creates ideal space for students to learn advanced packaging processes


BINGHAMTON UNIVERSITY

Innovative Technologies Complex 

IMAGE: 

THE INNOVATIVE TECHNOLOGIES COMPLEX AT BINGHAMTON UNIVERSITY, STATE UNIVERSITY OF NEW YORK

view more 

CREDIT: BINGHAMTON UNIVERSITY, STATE UNIVERSITY OF NEW YORK




BINGHAMTON, N.Y. -- A new $1 million in funding will help Binghamton University, State University of New York provide job training for more than 100 students a year in the growing advanced chip manufacturing industry.

The funding, announced today by U.S. Senate Majority Leader Chuck Schumer and U.S. Senator Kirsten Gillibrand, will help purchase equipment necessary to train students on the fundamentals of semiconductor and modern electronics manufacturing processes.

“With the semiconductor industry booming in Upstate NY, we need to start getting our students the hands-on training now to prepare them to fill these careers to ensure these projects will be a success,” said Schumer.

The Nanofabrication Lab (NLAB), located at the Innovative Technologies Complex, is a cleanroom used for advanced electronics packaging. The lab is part of S3IP, a New York State Center of Excellence that has over 120 companies performing research in electronics packaging and in areas relating to materials, failure analysis, and reliability testing. Additional equipment was needed to enhance the capabilities of the lab and get it up to today’s industry standards.

The $1 million in funding will purchase necessary equipment for the Nanofabrication Lab, pictured here.

The new equipment will allow the NLAB to serve as a teaching lab, where students will learn the protocols, techniques and skills necessary for working in a cleanroom environment, preparing them for job opportunities in the semiconductor and electronics manufacturing industry. The University expects to train at least 100 people each year, including graduate students, undergraduates, and local community members working in area industries or hoping to land jobs in those companies.

Binghamton University President Harvey Stenger said the project aligns perfectly with many of the campus’ key goals.

“As a premier public university, we focus on education as well as access,” he said. “We also recognize our role and responsibility when it comes to workforce development. Equipping our laboratories with the latest tools gives our students and our partners an important advantage. I’m grateful for Senator Schumer’s continued partnership, and I look forward to seeing our cleanroom serve as a learning space for our own undergraduates as well as high school and community college students from the region.”

A robust set of training opportunities will be made available through short courses and certificate/micro-credentialing programs. The facility will also support engagement activities with Historically Black Colleges and Universities through summer training programs and joint research projects. The first such HBCU joint program is expected to begin in June 2024.

Bahgat Sammakia, vice president for research and director of the S3IP Center of Excellence, said that efforts to reinvigorate the microelectronics industry in the United States rely on a skilled workforce.

“The workforce we need can only be a reality with improved opportunities for training,” he said. “Experience working with this state-of-the-art equipment in a cleanroom environment will give students a big boost when they enter the job market. And manufacturers in New York State and beyond will be able to recruit talented workers who have relevant expertise that can help their companies grow and thrive. Thank you, Senator Schumer, for this most recent support and for the CHIPS and Science Act, which is helping to fortify the entire semiconductor ecosystem.”

The Nanofabrication Lab (NLAB) at Binghamton University, State University of New York

CREDIT

Binghamton University, State University of New York